Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors

Madiha Bilal Qureshi,1 Muhammad Usman Tariq,1 Jamshid Abdul-Ghafar,2 Qurratulain Chundriger,1 Nasir Ud Din1 1Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan; 2Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Ch...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Qureshi MB, Tariq MU, Abdul-Ghafar J, Chundriger Q, Ud Din N
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
Acceso en línea:https://doaj.org/article/65ed29099ae44cb2a57adeb30fb51e40
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:65ed29099ae44cb2a57adeb30fb51e40
record_format dspace
spelling oai:doaj.org-article:65ed29099ae44cb2a57adeb30fb51e402021-11-30T18:50:36ZDiagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors1178-7074https://doaj.org/article/65ed29099ae44cb2a57adeb30fb51e402021-12-01T00:00:00Zhttps://www.dovepress.com/diagnostic-utility-of-tle1-transducer-like-enhancer-of-split-1-in-dist-peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Madiha Bilal Qureshi,1 Muhammad Usman Tariq,1 Jamshid Abdul-Ghafar,2 Qurratulain Chundriger,1 Nasir Ud Din1 1Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan; 2Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, AfghanistanCorrespondence: Jamshid Abdul-GhafarDepartment of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, AfghanistanTel +93 792 827 287Email jamshid.jalal@fmic.org.afBackground: Synovial sarcoma (SS) is a high-grade spindle cell tumor that accounts for 5% to 10% of soft tissue sarcomas. The majority originate from the deep intramuscular soft tissues of extremities with common sites including knee, ankle and feet. Immunohistochemical (IHC) stain TLE1 (transducer-like enhancer of split 1) is a potent diagnostic marker for distinguishing SS from mimicking tumors.Methodology: The study was performed on 177 tumor cases, including 89 SS and 88 non-synovial sarcoma (N-SS) cases which were diagnosed at Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, from July 2019 to June 2020. Hematoxylin and eosin (H&E) and IHC stained glass slides of these cases were reviewed. TLE1 expression was assessed based on the Remmele scoring system.Results: Eighty-nine cases of SS and 88 cases of N-SS were included in the study. SS cases included 42 (47.2%) monophasic subtype, 6 (6.7%) biphasic subtype and 41 (46.1%) poorly differentiated subtype. Major tumor types in N-SS cases were 27 (30.7%) Ewing sarcoma (ES), 13 (14.8%) leiomyosarcoma, 10 (11.4%) undifferentiated sarcoma (US), 8 (9.1%) fibrosarcomatous dermatofibrosarcoma protuberans and 7 (8%) malignant peripheral nerve sheath tumor cases. Mean patients’ age for SS cases was 26.14 years and for N-SS cases was 32.64 years. All 89 SS cases showed positive TLE1 expression. Out of 88 N-SS cases, 71 (80.7%) were TLE1 negative and 17 (19.3%) showed positive expression.Conclusion: This study shows that TLE1 is a very sensitive and relatively specific IHC marker for SS. TLE1 expression can be observed in other soft tissue sarcomas but diffuse strong TLE1 expression is highly specific for SS. The diagnosis should not solely rely on TLE1 expression and morphologic features but should include soft tissue specific lineage markers to avoid misdiagnosis.Keywords: synovial sarcoma, monophasic synovial sarcoma, TLE1Qureshi MBTariq MUAbdul-Ghafar JChundriger QUd Din NDove Medical Pressarticlesynovial sarcomamonophasic synovial sarcomatle1Medicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 9173-9179 (2021)
institution DOAJ
collection DOAJ
language EN
topic synovial sarcoma
monophasic synovial sarcoma
tle1
Medicine (General)
R5-920
spellingShingle synovial sarcoma
monophasic synovial sarcoma
tle1
Medicine (General)
R5-920
Qureshi MB
Tariq MU
Abdul-Ghafar J
Chundriger Q
Ud Din N
Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
description Madiha Bilal Qureshi,1 Muhammad Usman Tariq,1 Jamshid Abdul-Ghafar,2 Qurratulain Chundriger,1 Nasir Ud Din1 1Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan; 2Department of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, AfghanistanCorrespondence: Jamshid Abdul-GhafarDepartment of Pathology and Clinical Laboratory, French Medical Institute for Mothers and Children (FMIC), Kabul, AfghanistanTel +93 792 827 287Email jamshid.jalal@fmic.org.afBackground: Synovial sarcoma (SS) is a high-grade spindle cell tumor that accounts for 5% to 10% of soft tissue sarcomas. The majority originate from the deep intramuscular soft tissues of extremities with common sites including knee, ankle and feet. Immunohistochemical (IHC) stain TLE1 (transducer-like enhancer of split 1) is a potent diagnostic marker for distinguishing SS from mimicking tumors.Methodology: The study was performed on 177 tumor cases, including 89 SS and 88 non-synovial sarcoma (N-SS) cases which were diagnosed at Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, from July 2019 to June 2020. Hematoxylin and eosin (H&E) and IHC stained glass slides of these cases were reviewed. TLE1 expression was assessed based on the Remmele scoring system.Results: Eighty-nine cases of SS and 88 cases of N-SS were included in the study. SS cases included 42 (47.2%) monophasic subtype, 6 (6.7%) biphasic subtype and 41 (46.1%) poorly differentiated subtype. Major tumor types in N-SS cases were 27 (30.7%) Ewing sarcoma (ES), 13 (14.8%) leiomyosarcoma, 10 (11.4%) undifferentiated sarcoma (US), 8 (9.1%) fibrosarcomatous dermatofibrosarcoma protuberans and 7 (8%) malignant peripheral nerve sheath tumor cases. Mean patients’ age for SS cases was 26.14 years and for N-SS cases was 32.64 years. All 89 SS cases showed positive TLE1 expression. Out of 88 N-SS cases, 71 (80.7%) were TLE1 negative and 17 (19.3%) showed positive expression.Conclusion: This study shows that TLE1 is a very sensitive and relatively specific IHC marker for SS. TLE1 expression can be observed in other soft tissue sarcomas but diffuse strong TLE1 expression is highly specific for SS. The diagnosis should not solely rely on TLE1 expression and morphologic features but should include soft tissue specific lineage markers to avoid misdiagnosis.Keywords: synovial sarcoma, monophasic synovial sarcoma, TLE1
format article
author Qureshi MB
Tariq MU
Abdul-Ghafar J
Chundriger Q
Ud Din N
author_facet Qureshi MB
Tariq MU
Abdul-Ghafar J
Chundriger Q
Ud Din N
author_sort Qureshi MB
title Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
title_short Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
title_full Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
title_fullStr Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
title_full_unstemmed Diagnostic Utility of TLE1 (Transducer-Like Enhancer of Split 1) in Distinguishing Synovial Sarcoma from Mimicking Tumors
title_sort diagnostic utility of tle1 (transducer-like enhancer of split 1) in distinguishing synovial sarcoma from mimicking tumors
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/65ed29099ae44cb2a57adeb30fb51e40
work_keys_str_mv AT qureshimb diagnosticutilityoftle1transducerlikeenhancerofsplit1indistinguishingsynovialsarcomafrommimickingtumors
AT tariqmu diagnosticutilityoftle1transducerlikeenhancerofsplit1indistinguishingsynovialsarcomafrommimickingtumors
AT abdulghafarj diagnosticutilityoftle1transducerlikeenhancerofsplit1indistinguishingsynovialsarcomafrommimickingtumors
AT chundrigerq diagnosticutilityoftle1transducerlikeenhancerofsplit1indistinguishingsynovialsarcomafrommimickingtumors
AT uddinn diagnosticutilityoftle1transducerlikeenhancerofsplit1indistinguishingsynovialsarcomafrommimickingtumors
_version_ 1718406327614570496